Summary of indications and contraindications for Zilucoplan

Zilucoplan is a biological agent that targets the complement C5 protein and is used to treat a specific type of myasthenia gravis (generalized Myasthenia Gravis, gMG; rare disease). It was approved by the US FDA in 2023 with the trade name ILUBRYSQ. It is mainly targeted at adult patients who are AChR antibody positive, that is, the acetylcholine receptor antibody (AChR-Ab) positive group. This type accounts for approximately 85% of gMG patients, so the launch of Zilucoplan has high clinical value and fills the gap in complement inhibition therapy in this population.

The indications of Zeleptide are very clear, namely: the treatment of adult gMG patients with anti-AChR antibodies. Its mechanism is based on highly selective inhibition of the C5 component of the complement system, thereby blocking the formation of the C5a and C5b-9 terminal complex, thereby reducing immune attack on the neuromuscular junction. Clinical data shows that Zilucoplan can help improve symptoms of myasthenia, enhance muscle strength, and reduce breathing, swallowing, and movement disorders.

But not all patients are suitable for zeleptide. In terms of contraindication groups, the first thing to be vigilant about is patients who have not received Neisseria meningitidis vaccination, especially those with active infection or immunocompromised individuals. The use of complement inhibitors can significantly reduce the body's immune clearance ability against certain bacteria, especially Neisseria meningitidis. Therefore, it is strongly recommended that patients receive meningococcal vaccination before using Zilucoplan and closely monitor symptoms of infection during treatment.

In addition, patients with a history of allergy to Zilucoplan or its excipients, patients with active tuberculosis or uncontrolled HIV should also use it with caution. The safety of using zeleptide in pregnant or lactating women has not been fully established and needs to be judged by a professional physician based on the risk-benefit ratio. In summary, although Zilucoplan has significant efficacy in patients with AChR-Ab-positive gMG, comprehensive screening is required before use to avoid serious adverse events.

Reference materials:https://www.drugs.com/zilucoplan.html